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The genetic mechanisms underlying the poor prognosis of esophageal squamous cell carcinoma (ESCC) are not well understood. Here,
we report somatic mutations found in ESCC from sequencing 10 whole-genome and 57 whole-exome matched tumor-normal sample
pairs. Among the identified genes, we characterizedmutations inVANGL1 and showed that they accelerated cell growth in vitro.We also
found that five other genes, including three coding genes (SHANK2, MYBL2, FADD) and two non-coding genes (miR-4707-5p, PCAT1),
were involved in somatic copy-number alterations (SCNAs) or structural variants (SVs). A survival analysis based on the expression
profiles of 321 individuals with ESCC indicated that these genes were significantly associated with poorer survival. Subsequently,
we performed functional studies, which showed that miR-4707-5p and MYBL2 promoted proliferation and metastasis. Together, our
results shed light on somatic mutations and genomic events that contribute to ESCC tumorigenesis and prognosis and might suggest
therapeutic targets.Introduction
Esophageal squamous cell carcinoma (ESCC [MIM:
133239]) is a rapidly progressing cancer with poor
prognosis.1 The low efficacy of current treatments under-
scores the need to better understand the genetic mecha-
nisms driving tumor progression.2 Common germline
variants3–7 and somatic mutations,8,9 as well as copy-
number alterations,10 have been implicated in ESCC.
Recent studies on ESCC from high-risk areas
in China11–13 have highlighted the roles of multiple
recurrently altered genes in the pathogenesis of ESCC,
including TP53 (MIM: 191170), NOTCH1 (MIM:
190198), CDKN2A (MIM: 600160), and RB1 (MIM:
614041). A recent next-generation sequencing study
of ESCC identified mutations in the APOBEC family
of cytidine deaminases.14 However, a complete land-
scape of genetic lesions remains incomplete, and it
is likely that additional genes might also play a role
in this disease and its progression. The discovery of
these genetic lesions could become useful predictors
of survival or therapeutic targets. We used a variety
of methods including whole-genome and whole-
exome sequencing, gene expression profiling, cell
biology assays, and a xenograft mouse model study to
identify and characterize functional genes in ESCC
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Study Subjects
Individuals with ESCC were selected from the biobank of the
Sun Yat-Sen University Cancer Center (SYSUCC). In the whole-
genome sequencing (WGS) study, the criterions for inclusion
were as follows: (1) all subjects were histologically confirmed,
(2) the histological types of ESCC were clearly determined, and
(3) individuals did not receive chemotherapy or radiotherapy
before surgery. Tumor location included the upper, middle, and
lower thirds of the esophagus. Details on sample characteristics
are shown in Table S1. Esophageal tumor tissues and adjacent
normal esophageal tissues were dissected during surgery. The
tissues were frozen at 80C for subsequent DNA extraction.
Frozen tissues were re-examined by at least one certified patholo-
gist. Tissues were classified as ‘‘normal’’ if no tumor cells were
detected or classified as ‘‘tumor’’ if they contained at least 80%
malignant cells.
For the whole-exome sequencing (WES) study, we collected
60 tumor-normal pairs. The detailed information on the study
subjects is described in Table S1. To investigate the relationship
between gene expression and survival outcome, we evaluated
321 ESCC tumor-normal pairs, using the same criteria as described
above. The majority of cohort subjects were male (78.5%), the
mean age was 58.1 years (range: 34–84), and 81.3% (261) of
the ESCC individuals were at a late clinical stage (TNM stage:
IIb–IV). 142 of the 321 individuals were alive and 179 were
deceased at the endpoint of a five-year follow-up. Detailed patho-
logical characteristics of the individuals are provided in Table S2.ion Center for Cancer Medicine, Sun Yat-sen University Cancer Center,
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Clinical data of the studied subjects was collected from
medical records at SYSUCC. The information on survival status,
smoking, and alcohol consumption was collected via tele-
phone interview with ESCC-affected individuals or, if deceased,
through their first-degree relatives via a survey questionnaire.
Survival status was also confirmed by linking to the information
in the databases of the Death Registry of the Public Security
Department.
This study was approved by the human ethics committee at the
SYSUCC. All samples were collected with institutional review
board approval and with documented informed consent by all
participants.DNA Extraction and Quality Assurance
DNA extraction from the frozen tissues was conducted with a
QIAamp DNA Mini Kit (QIAGEN) according to the manufac-
turer’s protocol. DNA was quantified with Quant-iT PicoGreen
dsDNA quantitation reagent as specified by the manufacturer
(Invitrogen). The quality of DNA samples was confirmed by
Complete Genomics (CG) and by the genome sequencing core fa-
cility at Vanderbilt University.WGS, Data QC, and Variant Calling
We performed WGS on ten matched esophageal tumor-normal
genomes by using the cancer sequencing service of CG.
Data from the CG sequencer, based on iterative oligomer hy-
bridization,15 was analyzed with the CG analysis pipeline
(version 2.0). Reads were aligned to the NCBI Genome browser
reference genome (build 37.2), and single-nucleotide vari-
ants (SNVs), indels, and substitutions were called. For align-
ment in WGS, reads were initially mapped to the reference
genome with a fast algorithm, and these initial mappings were
refined by local de novo assembly, which was applied to all
regions that appear to contain variants from the initial map-
pings. The process of alignment has been described in previous
papers.16
For somatic variants (SNVs, small indels), each tumor sample
was compared to the baseline sample within the pair. The so-
matic variants that were unique to the tumor genome and not
present in the normal genome were identified by the statistic
somaticScore, indicating the quality for the somatic mutation
calls. Somatic scores of R10 (equivalent to SQHIGH) were
reported in our study. Somatic variants of SQHIGH indicated a
high quality of calling (i.e., it was reported that, for somatic var-
iants in the exome, the false positives had a 3% false discovery
rate at SQHIGH). The process of variant calling has been
described previously.15
For somatic copy-number variants (CNVs), coverage in the
tumor genome was normalized to coverage for the same region
in the matched normal genome. A hidden Markov model was
used to calculate CNVs in the genome. Segment plots were
generated with the Bioconductor R package called Gviz (version
1.10.3).17 Structural variants (SVs), including deletions, inver-
sions, tandem-duplications, distal-duplications, inter-chromo-
somal conjunctions, and complex variants, were identified
with the CG pipeline. Details on data quality control (QC), as-
sembly, and variant calling techniques have been previously
described.15,16
Somatic Circos plots were generatedwith the CGAssembly Pipe-
line version 2.0, and merged Circos plots for all samples were
generated with the RCircos R package18 based on the high-confi-710 The American Journal of Human Genetics 98, 709–727, April 7, 2dence conjunctions identified via the CG Pipeline. We excluded
the SVs involving human genomic repeats.
WES, Data QC, and Variant Calling
A total of 60 tumor-normal pairs were exome-sequenced with
paired-end DNA sequencing at the genome sequencing core facil-
ity at Vanderbilt University. The Agilent Sure-Select Human All
Exon V4 plus UTRs reagent targeting 335,765 human exons per
71.3 Mb in 190,414 genomic intervals was used as recommended
by the manufacturer to capture the exomes and adjacent UTRs. An
Illumina HiSeq2000 instrument was used to sequence the target
regions to generate paired-end reads (76 bp 3 2) with approxi-
mately 703 coverage per sample.
The FASTQ reads were subjected to initial data QC via QPLOT
to assess the performance of the sequence run. We also used
FastQC19 to evaluate the quality of the raw reads. Using UCSC
Genome Browser hg19 as the reference, we conducted sequence
alignment for samples that passed initial QC from FastQC by
using the Burrows-Wheeler aligner (BWA, version 0.6.2).20 Specif-
ically, reads were aligned to hg19 with the BWA software in
multi-threading mode with options ‘‘-q 20’’ to trim poor-quality
sequence bases in reads to ensure high-quality mapping. We
also used the option ‘‘-k 1 -n 5 -l 25’’ as the alignment mapping
parameters (taking the first 25 bp subsequence as the seed, the
maximum edit distance in the seed is 1 and the maximum edit
distance is 5).
After alignment by the BWA process, to improve variant
calling accuracy, we performed standard processing for re-
alignment of the BAM (Binary Alignment/Map) files before
somatic mutations calling. These steps included the removal
of duplicates (MarkDuplicates: identical 50 coordinates and
orientations and marks as duplicates), indel realignment
(IndelRealigner: perform local realignment of reads around in-
dels), and base recalibration (Base Quality Score Recalibration:
recalibrate base quality scores) with the Picard tools21 and the
GATK tool suite (the Genome Analysis Toolkit, Broad Insti-
tute).22 This approach has been widely used to improve variant
calling accuracy.
We assessed the mapping quality and evaluated the concor-
dance rate of known SNV calls. We further checked sample
contamination (or sample swaps) and mismatches by evaluating
the identical-by-descent matrix with germline variants (minor
allele frequency > 0.05). One sample failed the initial QC, and
two WES samples failed to pass the sample contamination QC
and were removed. The remaining 57 WES samples were used
for subsequent analysis.
For each sample, somatic SNVs and indels were called with
VARSCAN2.23 The BAM files were processed into pileup format
with SAMtools, skipping the alignments with a MAPQ (mapping
quality score, reported on a Phred scale) smaller than 1 (option
‘‘-q 1’’). We called somatic mutations with the default options
of the software, setting the minimum depth at 8 reads for the
normal and 6 reads for the tumors and the variant frequency to
call a heterozygote at >0.1. Somatic mutations were further
filtered to determine high-confidence calls via empirically derived
parameters, including a variant allele frequency > 10% in the tu-
mor and < 5% in the normal, and the one-tailed Fisher’s exact
test p value < 0.07. The Fisher’s exact test was conducted by
comparing the number of reference-supporting reads and the
number of variant-supporting reads in the tumor and normal
categories.23 We report only high-confidence somatic variants
in this study.016
Somatic copy-number alteration (SCNA) detection was based on
the quantification of deviations from the log-ratio of sequence
coverage depth within a tumor-normal pair.23 We used an empir-
ical threshold of log ratio (logR) > 1.5 for genomic amplification
and a log ratio < 1.5 for genomic deletion. Genome-wide
SCNA plots were generated with the in-house R scripts based on
the R package called gap.24Somatic Mutation Annotation, Filtering, and
Characterization
WGS variant data (masterVar/somaticVcfBeta) was manipulated
with the CGAtools version 1.7.0 package from CG. CG variant
files were converted to masterVar format and then to VCF format
with CGAtools. R25 and Python scripts were used for data
manipulation and figure preparation on our PowerWulf cluster
computers (PSSC Lab). Variant annotation was conducted with
ANNOVAR26 with publicly available databases, including the
1000 Genome Project database (1000 g2012apr_all, April 2012
version) and NHLBI exome sequencing project (NHLBI-ESP
6500, esp6500si_all).27 SNV annotation was based on dbSNP135
(snp135). Somatic variants were also annotated with COSMIC,
the Catalogue Of Somatic Mutations In Cancer (version 64, cos-
mic64). PolyPhen-228 (ljb_pp2) and SIFT29 (ljb_sift) whole-exome
scores were used to predict the potential biological function of
the variants.
After annotation, somatic SNVs were classified into several
categories based on genomic functional regions, including down-
stream, upstream, exonic, intergenic, intronic, 30 UTR, 50 UTR,
splicing sites, and non-coding RNA (ncRNA) and their potential
functional impacts (non-frameshift deletion and insertion, non-
synonymous and synonymous SNVs, frameshift indels, and
stop-gain and stop-loss variants). Loss-of-function (LOF) muta-
tions included frameshift indels, stop-gain and stop-loss variants,
and variants within splicing sites. Damaging variants were
defined as harmful and predicted as damaging by either Poly-
Phen-228 or SIFT2.29 We defined LOF mutations and damaging
variants as deleterious in this study. In addition, the novelty of
the variants was determined with information provided by
dbSNP (dbsnp135).
We also used SNPeFF (version 4.0) for annotation and vcf2maf
to generate a standard TCGA (The Cancer Genome Atlas project
of the International Genomics Consortium)Mutation Annotation
Format (MAF) file for the somatic SNVs. TheMAF format data were
used as input for the MutSigCV tool30 to identify the potential sig-
nificant genes.
To explore the roles of somatic mutations in regulatory ele-
ments, we annotated the whole-genome somatic mutations by
mapping the mutations to the non-coding regulatory regions
from the Encode Project and then focused on 57 chromatin immu-
noprecipitation sequencing (ChIP-seq) datasets generated from
histone-binding assays in six human cell lines (H1hesc, Hepg2,
Huvec, K562, Helas3, and Jurkat). In addition, we extracted all
somatic variants in flanking regions and UTRs of genes to identify
those variants mapping to known regulatory elements in the
genome. We used the original January 2011 ENCODE data freeze.
We reanalyzed the ENCODE data with the regulomeDB online
tool to profile the somatic variants in regulatory elements identi-
fied in all of the immortalized cell lines in ENCODE.
The genomic regions included promoters (active for H3K4me3
and H3K9Ac binding and repressive for H3K27me3 and
H3K9me3 binding), enhancers (active: H3K4me1 and H3K27Ac),The Amand elongation binding sites (active: H3K36me3, H3K79me2,
and H4K20me1).
Aggregation of Somatic Mutations, SCNAs, and
Hierarchical Clustering
We collapsed somatic variants into genes (NCBI build 37) or the
gene sets in known signaling pathways. Consecutive SCNAs,
including genomic amplifications and duplications, were merged
with Bedtools.31 Mutation frequency was calculated based on
the number of the ESCC-affected individuals who harbored the
observed somatic mutations out of all samples. We used the Kyoto
Encyclopedia of Genes and Genomes (KEGG) knowledge database
for the illustration of altered pathways. We used the R-package
hclust to conduct the hierarchical clustering for samples and so-
matic variants. Heatmap plots were generated with our in-house
R scripts based on the heatmap2 function in the R package called
gplots.32 Hierarchical clustering was conducted with the Hclust
method implemented in heatmap2 based on Euclidean distance
matrix.
Variant Validation
To validate the SNVs and small indels, we used the Sanger
sequencing method with BigDye Terminator chemistry on an
ABI3730XL automated sequencer (Applied Biosystems) according
to the protocol provided by the manufacturer. The somatic vari-
ants of interest were amplified by high-fidelity PCR, and then
the amplified PCR products were subjected to Sanger sequencing.
Gene Selection for RNAi-Screening Assay
We selected 19 genes that had at least one somatic mutation in the
studied subjects. We focused on previously uncharacterized genes,
excluding well-established oncogenes that have been extensively
studied (e.g., TP53, CDKN2A, and PIK3CA [MIM: 171834]).
We hypothesized that genes with deleterious somatic mutations
(LOF or damaging) would be more important in the pathogenesis
of ESCC. We focused on those previously uncharacterized recur-
rent mutations with potential function. After excluding genes
that have been comprehensively characterized in cancers (i.e.,
TP53,CDKN2A, andNFE2L2 [MIM: 600492]), we selected 13 genes
with deleterious mutations, namely, PABPC1 (MIM: 604679),
ASTN1 (MIM: 600904), AGAP3, VANGL1 (MIM: 610132), CDYL
(MIM: 603778), DHX33 (MIM: 614405), PLXNA2 (MIM:
601054), HCN1 (MIM: 602780), SCUBE3 (MIM: 614708),
DDX26B, NRXN1 (MIM: 600565), GIGYF2 (MIM: 612003), and
SYNPO2. Among them, eight genes carried LOF mutations,
including PABPC1, ASTN1, AGAP3, VANGL1, CDYL, DHX33,
NRXN1, and GIGYF2. In addition, we also included SOX11
(MIM: 600898) and SETBP1 (MIM: 611060), both of which
showed a relatively high frequency of mutations in UTR regions
(five individuals and three individuals affected, respectively).
Lastly, we included AFF3 (MIM: 601464) (two individuals affected
with two UTR mutations),WASF3 (MIM: 605068) (one individual
affected with two mutations), and two other genes (RSPO1 [MIM:
609595] and RSU1 [MIM: 179555]) for their potential functions
linked to cancer progression. Together, a total of 19 candidate
interested genes were selected for RNAi assay.
Cell Lines
ESCC cell lines TE-1 and EC109 were purchased from the Cell
Bank of the Chinese Academy of Sciences (Shanghai). ESCC cell
lines KYSE30, KYSE140, KYSE180, KYSE410, and KYSE510 wereerican Journal of Human Genetics 98, 709–727, April 7, 2016 711
generously provided by Professor Guan from SYSUCC. HEK293T
cells were obtained from the State Key Laboratory of Oncology in
South China (SYSUCC) and maintained in DMEM, and the other
cell lines were maintained in RPMI-1640. All medium contained
10% fetal bovine serum and 1 mM penicillin and streptomycin.Gene Expression Profiling for WGS Samples
Total RNA was extracted from tumor tissues and adjacent normal
tissues of ten samples also used for WGS. Each RNA sample was
quantified with the NanoDrop ND-1000 and RNA integrity was
assessed with denaturing agarose gel electrophoresis. The pooled
tumor RNA sample was generated by aliquoting an equal amount
of tumor RNA from these ten samples. The pooled control RNA
was generated from the normal RNA via the same method. After
initial quality assurance, mRNA was purified from total RNA after
removal of rRNA (mRNA-ONLY Eukaryotic mRNA Isolation Kit,
Epicenter). Then, each sample was amplified and transcribed
into fluorescent cRNA along the entire length of the transcripts.
The labeled cRNAs were hybridized onto the Human LncRNA
Array v.2.0 (8 3 60 K, Arraystar) and read on an Agilent Scanner
G2505C according to the manufacturer’s standard protocols.
Images were analyzed with the Agilent Feature Extraction software
(version 11.0.1.1). Data pre-processing was performed with the
GeneSpring GX v.11.5.1 software package (Agilent Technologies),
including background signal adjustment, poor signal filtering,
quantile normalization, and log transformation. Differentially
expressed long non-coding RNAs (lncRNAs) and mRNAs in the
pooled WGS samples were assessed by log fold change (FC).Analysis of Array-Based Gene Expression in ESCC
To explore the biological impacts of SCNAs, including recurrent
amplifications and deletions, we evaluated the correlation of
SCNAs with global gene expression. We used both the in-house
generated dataset of mRNA and lncRNA expression data (see
Gene Expression Profiling for WGS Samples) and two publicly
available datasets in the NCBI GEO repository, including GEO:
GSE23400 (n ¼ 53, Affymetrix Human Genome U133 Set
U133A)33 and GEO: GSE20347 (n ¼ 17, Affymetrix HG-U133A
2.0).34 Both GEO datasets were derived from mRNA arrays used
to profile gene expression in ESCC tumor tissue as compared to
their matched normal tissue. We included these two microarray
datasets for the following reasons: (1) both studies were conducted
by the same lab with the same platform (Affymetrix Human
Genome U133A 2.0 Array), and (2) QC, background correction,
and normalization were conducted with the same normalization
method, the Robust Multiarray Average (RMA) algorithm imple-
mented in Bioconductor in R. Additionally, (3) the results have
been validated by the authors, and also have been used or vali-
dated in several other studies. Therefore, the data generated might
represent a subset of ESCC differentially expressed genes with a
relatively low false-positive rate.
Data pre-processing was performed (for the un-preprocessed da-
taset) with the GeneSpring GX (Agilent Technologies, see Gene
Expression Profiling for WGS Samples above). Differentially ex-
pressed genes between tumor and normal samples were identified
with a paired t test and fold change. Hierarchical clustering was
performed based on the Euclidian distance matrix.Pathway Analysis
To explore the information on somatically mutated genes and
differentially expressed genes, we conducted pathway analysis712 The American Journal of Human Genetics 98, 709–727, April 7, 2with the David Bioinformatics Functional Annotation Tools and
visualized altered genes in significantly enriched pathways with
the Bioconductor R package called pathview.
Specifically, we conducted an enrichment analysis by using
David Bioinformatics Functional Annotation Tools for somatically
mutated genes. Separately, we conducted enrichment analyses
with differentially expressed genes (combinations of differential-
expression gene sets from GSE23400, GSE20347, and an in-house
microarray dataset) and SCNA-affected genes. We then over-laid
the same pathways with the above-mentioned three layers of an-
alyses by using the Pathview tool and highlighted the altered
genes enriched in the pathways. This combined analytical
approach enabled us to illustrate the altered pathways by using
different types of genomic data and expression data that might
reflect the biological nature of altered genes in the pathways.
Real-Time qPCR Assays
Total RNA from tissue and cell lines was extracted with Trizol
(Invitrogen). Reverse transcription was performed with the Prime-
Script RT reagent kit (Takara). We performed qPCR analysis with
Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) by using
a LightCycler480 Real-Time PCR Detection System (Roche). Rela-
tive expression of targets was calculated with the following equa-
tions: relative quantity ¼ 2DCt, DCt ¼ Ct (target) – Ct (reference).
The primers for the target coding genes and lncRNAs are listed in
Table S3. Primers for microRNA reverse transcription and qPCR
were purchased from RiboBio (Guangzhou).
siRNA and miRNA Transfection
For siRNA and miRNA transfection, Lipofectamine RNAiMAX
Reagent (Invitrogen) was used according to the manufacturer’s
instructions. siRNA and miRNA mimics were purchased from
RiboBio (Guangzhou). The sequences are shown in Table S3.
Generation of Lentivirus-Mediated Overexpressing
Cells
Overexpressing lentiviruses were generated by co-transfection of
PCDH-copGFP (System Biosciences) and the packing vectors
psPAX2 and pMD2.G into HEK293T. After cells were infected,
the GFP-positive cells were collected by fluorescence-activated
cell sorting. Primers for plasmid construction are listed in Table S3.
Short-Term Cell Proliferation Assays
Cells were placed into 96-well plates at 33 103 to 43 103 cells per
well and incubated for 3–7 days. TheMTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) assay was performed as
previously described.35
Colony Formation Assay
5 3 102 to 3 3 104 cells were placed into six-well plates and incu-
bated for two weeks. The number of clones was counted after
staining with crystal violet.
Cell-Cycle Analysis
Cells were harvested after transfection (24 hr), washed with ice-
cold PBS, and fixed in 75% ice-cold ethanol at 20C for 1 hr.
RNaseA (TakaRa) was added at a final concentration of 50 ug/ml,
and the cells were incubated at 37C for 30 min. For staining, cells
were incubated in 20 ug/ml propidium iodide (PI, Life Technolo-
gies) for 30 min at 4C. The treated cells were collected and016
analyzed on a flow cytometer (Cytomics FC500, Beckman
Coulter).
Transwell Migration and Invasion Assay
The migration and invasion ability of cells was determined by the
Transwell chamber assay as previously described.36 43 104to 103
104 cells were seeded onto the top chamber of the 24-well polyeth-
ylene terephathalate filter with 8 mm pores (BD Falcon) while the
bottom chamber was filled with 600 ul RPMI1640 with 10% fetal
bovine serum. After 20 hr, cells that crossed the membranes were
fixed with crystal violet and counted. For the invasion assay, a
Matrigel-covered Transwell chamber (BD Falcon) was used.
TMAs and IHC
Formalin fixed, paraffin-embedded tissue microarrays (TMAs),
including 120 primary ESCC tumors and 85 normal tissues, were
used for immunohistochemistry (IHC). TMA slides were depar-
affinized in xylene, rehydrated with ethanol, and incubated for
10 min in 3% hydrogen peroxide to quench endogenous peroxi-
dase activity. For antigen retrieval, slides were heated with citrate
buffer in a pressure container for 5 min and cooled at room tem-
perature. The TMAs were incubated overnight at 4C with the an-
tibodies listed in Table S3. The nucleus was counterstained with
hematoxylin. The results were independently evaluated by two
pathologists on the basis of the following criteria—(1) staining in-
tensity: zero (negative), 1 (weak), 2 (moderate), and 3 (strong) and
(2) percentage of positive cells: 1 (%25%), 2 (25%–50%), 3 (50%–
75%), and 4 (75%–100%). A non-parametric Wilcoxon rank sum
test was used for the comparison of protein amounts between tu-
mor and normal tissues.
Western Blotting
Western blot analysis was performed according to the standard
protocol. Antibodies used are shown in Table S3.
miRNA Targets Prediction and Luciferase Reporter
Assay
miRNA targets were predicted with TargetScan37 and miRDB38,39
software. The full length of the 30 UTRs of the target genes were
cloned into the pmirGLO Dual-Luciferase miRNA Target Expres-
sion Vector (Promega) (Table S3). The mutated vectors were con-
structed with the QuickChange Multi Site-Directed Mutagenesis
Kit (Agilent Technologies). The site-directed mutation primers
used are shown in Table S3. For the luciferase assay, vectors were
co-transfected into HEK293T cells with either a negative control
or miRNA mimics. 24 hr later, the luciferase activity was deter-
mined by the Dual-Glo Luciferase Assay System (Promega) and a
TD-20/20 luminometer (Turner Designs).
Luciferase Assays for TOP-flash
Measurement of Wnt signaling was performed with the TOP-flash
assay.40 HEK293T cells were cotransfected with pcDNA3.1-Wnt1
with pcDNA3.1-VANGL1 or mutants of pcDNA3.1-VANGL1.
Luciferase activity was assessed according to the Dual-Glo Lucif-
erase Assay System (Promega) 24 hr after transfection.
Xenografts in BALB/C-nu/nu Mice
All animal experiments were conducted following the guidelines
of the institutional animal care and use committee at SYSUCC.
Six-week-old age-matched BALB/C-nu/nu nude mice were used
for lung metastasis assays41 and lymph node metastasis assays.42The AmFor the lung metastasis assay, 2 3 106 cells, resuspended in
RPMI1640, were injected into the tail vein. After 12 weeks, mice
were sacrificed, the lungs were serial sectioned, and the extent of
metastasis was determined by H&E staining and microscopic
examination. For the lymph node metastasis assay, 2 3 106 cells,
resuspended in RPMI1640, were injected into the footpad. After
8 weeks, all the popliteal lymph nodes and inguinal lymph nodes
were evaluated for metastases by H&E staining.
Survival Analysis
The Cox proportional-hazards model was used for survival anal-
ysis with the R package called survival. We used a p value cutoff
of<0.05 as statistical significance. For gene expression, we dichot-
omized gene expression values into low- and high-level groups by
using an optimal cutoff value that maximizes sensitivity and spec-
ificity in the receiver operating characteristic (ROC) curve.
For SCNAs, ESCC-affected subjects with a given recurrent amplifi-
cation or deletion were designated as ‘‘1,’’ whereas unaffected
individuals were designated as ‘‘0.’’ To evaluate hazard ratios (HRs)
for deregulated gene expression, we adjusted for sex, age, clinical
stage, smoking, and alcohol drinking in the Cox regressionmodels.Results
In this study, 67 somatic genomes of ESCC were compre-
hensively characterized via WGS and WES. We described a
landscape of genetic lesions, including somatic SNVs,
small indels, and SVs and/or SCNAs. To investigate the mo-
lecular functions of the somatically altered genes in ESCC,
we conducted functional analysis by using biological assays
and evaluated the influence of their expression onprognosis
in a large clinical cohort (n¼ 321). Finally, enrichment anal-
ysis was conducted to explore a potential joint effect of
altered genes at the genomic and transcriptional levels on
ESCC development. See Figure 1 for the workflow of our
studies.
Sequence Analysis and Somatic Mutation
Identification
An average read coverage of approximately 50-fold was
obtained in the ten pairs of WGS samples. For WES, we ob-
tained approximately 72-fold read coverage in 57 tumor-
normal pairs of samples. In the WES samples, 90% of
genetic variants were SNVs, 5% were deletions, and 4%
were insertions. Additionally, 27% of identified variants
were novel. See Figure S1 for the Ti/Tv profiles in samples.
A totalof 19,434somaticmutationswithin71.3Mbof tar-
geted regions (335,765 exons) were found in the combined
WGS and WES data (Table S4). Table S5 lists the details of
the somatic variants identified in exomes. Figure S2 depicts
the somatic variant distributions across genomic functional
regions (WGS). Sanger sequencing on a subset of variants
confirmed 82% (83 variants) of somatic variants identified
byWGSand93% (84variants) byWES.A list of somaticmu-
tations identified by WGS and WES that have been vali-
dated by Sanger sequencing is provided in Table S6.
For exonic mutations, we identified 4,582 (24%) somatic
mutations in coding regions. Previously reported genes inerican Journal of Human Genetics 98, 709–727, April 7, 2016 713
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Figure 1. Illustration of the Experimental
Design and Analyses
Initially, we conducted WGS with 10
tumor-normal pairs and WES with 60 tu-
mor-normal pairs. One sample failed the
initial QC, and two WES samples failed to
pass the sample contamination QC and
were removed. The remaining 57 WES
samples and 10 WGS samples were used
for subsequent analysis (n ¼ 67). We used
the CG pipeline 2.0 for variant calling,
filtering for WGS, and VARSCAN for WES.
We combined high-confidence somatic
variants from WGS and WES somatic mu-
tations within 71.3 Mb of targeted regions
and applied these variants to annotation
and summarization. For gene expression
analysis, we used in-house microarray
data and two ESCC microarray datasets
from the NCBI GEO database (see Material
and Methods) to generate a differential
expression (DE) gene set. Finally, genes
from genomic data analysis and expression
data analysis were subjected to biological
studies and/or analysis in a large cohort.
Three types of analyses were performed:
(1) functional analysis: RNAi for 19
genes with LOF mutations and identified
as uncharacterized based on a literature
search; (2) survival analysis (n ¼ 321);
and (3) pathway-based analysis for differ-
entially expressed genes, mutated genes,
and SCNV genes.ESCC were frequent targets: TP53 (67% of cases have non-
synonymous mutations or UTR/splicing-site mutations),
TTN (21% [MIM: 188840]), NOTCH1 (19%), NFE2L2
(13% [MIM: 600492]), and CDKN2A (10%) (Figure 2A).
We characterized mutations by either PolyPhen-228 or
SIFT229 and found that 409 (2%) of somatic mutations
were predicted to result in loss-of-function mutations
and 1,381 (7%) were classified as damaging (Table S4).
We also conducted bioinformatics analysis to identify
significant genes in our genomic data. We used the
MutSigCV software43 for gene identification because of
its wide use in cancer studies. As a result, TP53, CDKN2A,
NOTCH1, and NFE2L2 were ranked at the top of the gene
list, with q values < 0.05 (Table S7). Of note, our
sequencing coverage and the limited sample size might
be underpowered to detect other significant genes with
rare mutations.
For somatic mutations in regulatory regions, we
analyzed mutations in flanking regions, UTRs, transcrip-714 The American Journal of Human Genetics 98, 709–727, April 7, 2016tional binding sites (TBSs), histone
binding sites, or other regulatory ele-
ments of genes. See Figure S2 for the
distributions of the variants in WGS
samples, and see Table S8 for details
of the somatic mutations within
flanking regions and UTRs mapping
to the ENCODE regulatory database
using Regulomedb tool.To determine which somatic mutations were correlated
with overall survival, we evaluated the correlations of all
genes with deleterious recurrent mutation frequencies
greater than 7% in the WES samples. Of these, NOTCH1
provided the strongest evidence as a predictive marker
for ESCC prognosis and was correlated with ESCC overall
clinical stage (p ¼ 0.0096) and WHO T stage (p ¼ 0.047)
(Figure S3A). Survival analysis showed that individuals
with deleterious NOTCH1mutations had a better outcome
than those individuals without deleterious mutations
(Figure S3B). But these results were preliminary due to
our limited sample size. We further investigated the poten-
tial correlation of NOTCH1 gene expression and ESCC sur-
vival by using a large sample set (n¼ 321). Individuals with
lower expression of NOTCH1 had a higher 5-year overall
survival (OS) rate than those with higher NOTCH1 levels
(54.6% versus 39.7%, respectively). And the median OS
was 50 months and 29.6 months, respectively (log-rank
test p ¼ 0.006) (Figure S3C). Univariate analysis using
Figure 2. Top Recurrent Genes Harbored Exonic Somatic Mutations in 67 ESCC Samples
(A) Upper panel, bar plot for the somatic mutation rates per Mb in tumor genomes. Lower panel, occurrence of top-ranked somatically
mutated genes identified byWGS andWES. Each vertical bar represents an individual with a somatic mutation in the specified gene. For
the exonic category (green), we excluded silent substitutions, mutations in the upstream or 50 flank, the downstream or 30 flank, and
intergenic and intronic regions (IGRs). LOF (red) mutations include frameshift mutations, stop-gain and stop-loss mutations, and mu-
tations within splicing sites. LOF and predicted damaging mutations were designated as deleterious (orange). Right panel, the x axis in-
dicates the proportion of individuals harboring somatic mutations in the specific gene.
(B) 5 out of 19 mutated genes showed significant effects on cell growth in ESCC cell lines (KYSE30, EC109) in RNAi knockdown assays
(seeMaterial andMethods). The bars represent themean5 SD; nc, the siRNA negative control with a nonsense and scrambled sequence;
*t test p value < 0.05, **p value < 0.01, ***p value < 0.001.Cox’s proportional hazard model showed that NOTCH1
(along with other clinical characters as showed in Table 1)
was significantly correlated to OS with an HR of 1.60 (95%
confidence interval [CI] ¼ 1.14–2.25, p ¼ 0.007). Multi-
variate Cox regression analysis indicated that NOTCH1
expression, after adjustment for age, sex, tumor stage,
smoking, and alcohol consumption, was significantly asso-
ciated with OS (HR ¼ 1.51, 95% CI ¼ 1.06–2.15, p¼ 0.022)The Am(Table 1). Our study suggests that loss of function of
NOTCH1 by deleterious mutations or by downregulated
expression prolongs survival of ESCC-affected individuals.
We also employed an RNAi screening assay with the
ESCC cell lines KYSE30 and EC109 to knock down 19 pre-
viously uncharacterized genes with deleterious mutations
identified in this study (see Gene Selection for RNAi-
Screening Assay in Material and Methods for details).erican Journal of Human Genetics 98, 709–727, April 7, 2016 715
Table 1. Survival Analysis for Clinical Demographics and Gene
Expression in 321 Subjects with ESCC
Analysis Variable HR (95% CI) p Value
Univariate
Gender (male/female) 0.87 (0.60, 1.25) 0.447
Age (< 58 /R 58) 1.66 (1.22, 2.25) 0.001a
Tumor size (< 4.0 cm /R
4.0 cm)
0.96 (0.71, 1.29) 0.765
Tumor location (upper/middle/
lower)
0.70 (0.53, 0.91) 0.009a
Histologic grade (G1/G2/G3) 1.29 (1.05, 1.58) 0.017b
T status (T1-2/T3-4) 1.30 (0.88, 1.92) 0.183
Lymph node metastasis (N0/
N1/2/3)
1.65 (1.40, 1.95) <0.001c
M status (M0/M1) 2.27 (1.29, 3.99) 0.005a
Stage 10 (I-IIa/IIb-IV) 2.96 (1.82,4.83) <0.001c
Smoking 1.20 (0.86, 1.69) 0.280
Alcohol drinking 1.02 (0.75, 1.37) 0.922
NOTCH1 expression (low/high) 1.60 (1.14, 2.25) 0.007a
MYBL2 expression (low/high) 1.60 (1.15, 2.23) 0.005a
FADD expression (low/high) 1.58 (1.18, 2.12) 0.002a
FGF19 expression (low/high) 1.25 (0.86, 1.82) 0.236
SHANK2 expression (low/high) 2.48 (1.50, 4.10) <0.001c
PCAT1 expression (low/high) 1.52 (1.03, 2.24) 0.035b
miR-4707-5p expression (low/
high)
1.46 (0.96, 2.21) 0.077
Multivariated
NOTCH1 expression (low/high) 1.51 (1.06, 2.15) 0.022b
MYBL2 expression (low/high) 1.56 (1.11, 2.19) 0.010b
FADD expression (low/high) 1.63 (1.20, 2.21) 0.002a
FGF19 expression (low/high) 1.08 (0.74, 1.60) 0.685
SHANK2 expression (low/high) 2.51 (1.49, 4.22) 0.001a
PCAT1 expression (low/high) 1.75 (1.15, 2.67) 0.009a
miR-4707-5p expression (low/
high)
1.71 (1.10, 2.65) 0.016b
ap < 0.01.
bp < 0.05.
cp < 0.001.
dAdjusted for age, sex, stage, smoking, and alcohol.Both cell lines lacked mutations in these genes. We found
that five genes were associated with ESCC cell growth,
including VANGL1 (MIM: 610132), SCUBE3 (MIM:
614708), SOX11 (MIM: 600898), RSU1 (MIM: 179555)
and RSPO1 (MIM: 609595) (Figure 2B), of which, VANGL1
showed the largest effect.
Characterization of the Roles of VANGL1 Somatic
Mutations in ESCC
VANGL1 encodes a transmembrane protein that has been
implicated in cancer. However, its roles and mechanisms716 The American Journal of Human Genetics 98, 709–727, April 7, 2in ESCC development have not been determined. Among
our 67 samples, we identified two deleterious muta-
tions in VANGL1 (GenBank: NM_001172412.1), a stop
gain (c.1013C>A [p.Ser338*]) and a nonsynonymous mu-
tation (c.464C>G [p.Ser155Cys]). The p.Ser338* variant is
predicted to cause premature termination in the cytosolic
C-terminal domain. Three other somatic mutations of un-
known significance were identified in the 30 UTR, yielding
a total of 6% of studied subjects with a VANGL1 mutation
(Figure 3A).
Suppression of VANGL1 with siRNA promoted the pro-
liferation of KYSE30 andKYSE140 cells (Figure 3B), whereas
exogenous expression of VANGL1 inhibited the KYSE510
cell growth (Figure 3C). Furthermore, VANGL1 expression
vectors containing either of the two deleterious mutations
identified by sequencing, including p.Ser155Cys (referred
to asM1) and p.Ser338* (referred to asM2), accelerated pro-
liferation of KYSE510 cells (Figure 3C). VANGL1 has been
reported to inhibit the Wnt/b-catenin signaling pathway
in Drosophila.44 In our study, a TOP-FLASH luciferase re-
porter assay showed that overexpression of the wild-type
VANGL1 inhibited the Wnt1-mediated TOP-FLASH activa-
tion in a dose-dependent manner (Figure 3D). In contrast,
VANGL1 mutants showed a reversed effect as compared to
the wide-type; notably, VANGL1-M2 (p.Ser338*) substan-
tially enhanced the TOP-FLASH activation (Figure 3D).
Subsequent immunofluorescence and Western blot assays
showed that VANGL1 knockdown promoted b-catenin
translocation from the cytoplasm to the nucleus (Figures
3E and 3F). Also,VANGL1 suppression upregulated the pro-
tein amount of c-Myc in KYSE30 and KYSE140 cells
(Figure 3E). Our results indicate that VANGL1 functions
as a tumor suppressor in ESCCby inhibitingWnt/b-catenin
signaling activity.
Analysis of Structural Variants and Tandem
Duplications of MYBL2
We also analyzed genomic rearrangement events detected
by the CG Pipeline 2.0 (Figure 4A and Figure S4) in the
WGS tumors. A total of 739 (39 to 147per sample) high-con-
fidence somatic rearrangements were found, including 278
deletions (38%), 147 inversions (20%), 124 duplications
(17%), 29 interchromosomal translocations (4%), and 161
complex structural variants (22%) (Table S9 and Figures 4B
and 4C). Structural variants (SVs) of multiple cancer-related
genes were observed, including deletions of tumor suppres-
sor genes (TP53, CDKN2A, NFE2L2, LRP1B [MIM: 608766],
FHIT [MIM: 601153], TGFBR2 [MIM: 190182], and FOXP1
[MIM: 605515]), fusions of oncogenes (RUNX1T1-PHACTR1
[MIM: 133435, 608723], MAML2-TTC28 [MIM: 607537,
615098], ASXL1-RNF170 [MIM: 612990, 614649], FGF19-
SHANK2 [MIM: 603891, 603290]), and amplifications of
oncogenes (e.g., tandem duplications of MYBL2 [MIM:
601415]) (Figure 4D and Table S9).
MYBL2, a member of the MYB family of transcription
factor genes, has been implicated as a nuclear protein
involved in cell-cycle progression. In our WGS samples,016
Figure 3. VANGL1 as a Functional Tumor
Suppressor through the Inhibition of the
Wnt/b-catenin Pathway in ESCC
(A) Diagram of somatic mutations within
VANGL1 identified in WES study subjects.
(B) siRNA knockdown of VANGL1 expres-
sion increased KYSE30 and KYSE140 cell
proliferation (MTT assay). Two different
siRNAs (VANGL1-si1 and VANGL1-si2)
were tested in triplicate.
(C) As compared to wild-type,VANGL1mu-
tants enhanced proliferation of K510 cells.
(D) Luciferase reporter assays indicated
that the wild-type VANGL1 gene inhibited
the Wnt1 mediated activation of TOP-
FLASH in a dose dependent manner as
compared to its mutants (VANGL1-M1
and VANGL1-M2). 10 ng, 20 ng or 40 ng
of VANGL1, VANGL1-M1, or VANGL1-M2
were co-transfected with 5 ng Wnt1 into
HEK293T cells.
(E) Western blots of b-catenin and its target
gene c-Myc in KYSE30 and KYSE140 cells
transfected with siRNA. Histone H3 and
GAPDH were used as loading controls.
(F) VANGL1 knockdown upregulated the
protein level of b-catenin and promoted
b-catenin translocation from the cyto-
plasm to the nucleus in KYSE30 and
KYSE410 cell lines. b-catenin was stained
with red, and nuclei were counterstained
with DAPI (blue).
Scale bars, 100 mm. NC, the siRNA negative
control with a nonsense and scrambled
sequence. The experiment was conducted
in triplicate. The bars shown in (B)–(D)
represent mean 5 SD; *, #t test p values <
0.05.we found seven of ten ESCC tumors had tandemly
repeated duplications of MYBL2. MYBL2 protein amount
and mRNA expression were also significantly upregulated
in tumors (p < 0.001) (see Figure 4E for IHC staining and
Figure 4F for qPCR). The correlation between MYBL2
expression and its DNA copy number was significant (cor-
relation coefficient ¼ 0.748, p < 0.001) (Figure 4G).
In the survival analysis performed, individuals with
elevated copies of MYBL2 showed a worse prognosis (p ¼
0.001, n ¼ 68) (Figure 4H), as did individuals with high
MYBL2 expression (log-rank p value ¼ 0.005, n ¼ 321)
(Figure 4I). The adjusted HR is 1.56 (95% CI ¼ 1.11–2.19)
(Table 1). Knockdown of MYBL2 expression with siRNA
decreased cell proliferation, colony formation, and migra-
tion of KYSE30 and KYSE410 cells (Figures 4J–4L and Fig-
ures S6A–S6D). In addition, in vitro experiments suggested
that MYBL2 regulates cell proliferation by modulating the
cell cycle (Figure 4M and Figure S6E). Collectively, our find-
ings indicateMYBL2 as an important oncogene in ESCC, as
has been previously shown in other cancers.45
Identification of SCNAs in ESCC
SCNAs, including amplifications and deletions, are among
the most important genomic events in tumors but are
largely uncharacterized in ESCC. In this study, we usedThe Amcoverage-based algorithms to call SCNAs from WGS
and WES samples.15,23 In our WGS data we detected
1,239 SCNAs with relative coverage greater than 2 and
7,586 with an absolute log ratio greater than 2. The SCNAs
identified in the WES samples were consistent with the
WGS findings and included a series of distinctive gene
duplications within 1p36, 2q16, 3p24.3, 8p23.3, 10q21,
11q13.2-11q13.4 (the ‘‘FGFs-FADD [MIM: 602457]-
SHANK2’’ region), 11q22 (the ‘‘CASP [MIM: 116896]-
MMPs’’ region), and 14q21.1 (Figures 5A and 5C). The
ESCC genomes had a pattern of amplifications and dele-
tions characteristic of C class tumors.46 The amplified
SCNAs included TP73 (MIM: 601990) on 1p36, SOX2
(MIM: 184429)47 on 3p24.3, FGFs (FGF19, FGF4 [MIM:
164980], and FGF3 [MIM: 164950]), SHANK2 in 11q13.2-
11q13.4, FOXA1 (MIM: 602294) on 14q21.1, and MYC
(MIM: 190080) on 8p23.3.48,49 In addition to amplifi-
cations, we also detected a group of specific recurring
deletions including 9p21.3 (the ‘‘MTAP [MIM: 156540]-
CDKN2A/2B-CDKN2B-AS1 [MIM: 613149]’’ region)
(Figure 5A). Notably, CDKN2A also carried recurrent delete-
rious somatic mutations in our study subjects (Figure 2A).
In our 57 WES tissue samples, high-frequency recurrent
SCNAs (i.e., >10% of cases affected) included 206 amplifi-
cations and 111 deletions. Figure 5B shows the top 10erican Journal of Human Genetics 98, 709–727, April 7, 2016 717
Figure 4. Structural Variants and Functional Studies of MYBL2
(A) The merged Circos plot of the somatic junctions identified in theWGS samples. Orange lines indicate inter-chromosomal junctions;
gray lines indicate intra-chromosomal translocations.
(B) The vertical bar plot represents high confidence structural variation (SV) counts in 10 WGS study subjects.
(legend continued on next page)
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amplifications and deletions identified. Of note, 47% of
ESCC samples had recurrent SCNAs within 11q13.2–
11q13.4 (the ‘‘FGFs-FADD-SHANK2’’ region), and 30%
of samples had SCNAs within the CDKN2A deletion
(9p21.3, chr9: 21,967,078–22,009,304) (Figures 5A and
5B). Interestingly, a previous study that investigated the
temporal and spatial evolution of somatic chromosomal
alterations in esophagus cancer (MIM: 133239) showed
that the 9p21.3 deletion was shared in common with Bar-
rett esophagus (MIM: 614266) and esophageal adenocarci-
noma (EAC [MIM: 614266]),50 suggesting that 9p21.3
deletion might be an important early event common to
different types of esophageal cancers. Together, approxi-
mately 65% of individuals were affected with an SCNA
that included 11q13.2–q13.4 or 9p21.3. Of note, some
cases had SCNAs involving both regions.
Expression and Survival Analysis of SCNA-Harboring
Genes in ESCC
To investigate the impact of SCNAs on gene expression,
we evaluated the expression amounts of 20 protein-coding
genes with qPCRwithin the amplified regions on 3q26.33–
3q27.1, 8q24.21, 11q13.3–11q13.4, and 14q21.1–14q11.2.
We observed that seven genes exhibited elevated expres-
sion in ESCC tumor tissues as compared with the adjacent
normal control tissue (Figure 6A and Table S10). For non-
coding genes, we identified 17 miRNAs and three lncRNA
genes (SHANK2-AS1, LINC00888, and PCAT1 [MIM:
616043]) within SCNA regions with abnormal expression
in tumors as compared to expression in adjacent normal
tissue (Figure 6B and Table S10). Using an independent
sample set (n ¼ 50 tumor-normal pairs), we found that
three coding genes (FADD, FGF19, SHANK2) (Figure 6C)
and four non-coding genes (miR-4707-5p, miR-1224-3p,
PCAT1, miR-4448) (Figure 6D) within SCNA regions were
statistically overexpressed in tumors.
To investigate the roles of the deregulated genes within
recurrent SCNA regions, using a large sample set (n ¼
321), we conducted a survival analysis with three coding
genes (FADD, FGF19, SHANK2) and two non-coding genes
(miR-4707-5p, PCAT1). We found that FADD, SHANK2,
miR-4707-5p, and PCAT1 overexpression was signifi-
cantly associated with poorer ESCC survival (Table 1 and
Figure 6E).(C) The pie chart illustrates the fractions of SVs in different categorie
cation, inter-chromosomal conjunction, and complex.
(D) The recurrent gene amplifications and deletions (R2 cases obser
ESCC individual; green color indicates the individual carrying the gen
the gene duplication.
(E and F) The protein level andmRNA expression ofMYBL2were high
measured by IHC (E) and qPCR assay (F), respectively.
(G) The positive correlation between MYBL2 DNA copy-number and
(H) Higher DNA copy-number of MYBL2 was significantly associated
(I) Upregulation of MYBL2 was significantly associated with poor su
(J–M) siRNA knockdown ofMYBL2 in KYSE30 and KYSE410 cell lines d
(L). All experiments were conducted in triplicate. (M) Flow cytometry
fected with MYBL2 siRNAs. Experiments were conducted in triplicat
sequence. The bars shown in (J)–(M) represent the mean5 SD; *, #t
The AmSHANK2, located in the 11q13.3–11q13.4 amplified
SCNA, had the largest effect size on ESCC survival. The
adjusted HR was 2.51 (95% CI ¼ 1.49–4.22) (Table 1).
Kaplan-Meier curves and results of the log-rank tests indi-
cated that individuals with higher expression of SHANK2
showed poorer survival (log-rank p value < 0.001). Two
other genes in the same SCNA, FADD and FGF19, were
also studied. For FADD, the group with higher expression
showed a poorer survival (log-rank p value ¼ 0.002), with
an adjusted HR of 1.63 (95% CI ¼ 1.20–2.21), but no asso-
ciation between FGF19 and ESCC survival was observed
(Table 1).
For non-coding genes, survival analysis showed that in-
dividuals with higher PCAT1 expression had a worse prog-
nosis (log-rank p value ¼ 0.032), the adjusted HR was 1.75
(95% CI ¼ 1.15–2.67). Likewise, for miR-4707-5p, the high
expression group had a poorer survival (log-rank p value ¼
0.074) and the adjusted HR was 1.71 (95% CI ¼ 1.10–2.65)
(Table 1 and Figure 6E).
Functional Analyses of the ncRNA Genes
In cell culture, we observed that overexpression of PCAT1
and miR-1224-3p (Figures 6F and 6G and Figure S7)
increased growth and colony formation, whereas over-
expression of miR-4707-5p promoted cell migration and
invasion in KYSE30 and KYSE180 cells (Figure 6H and
Figure S8).
To determine the effect of miR-4707-5p on metastasis,
we performed two different nude mouse xenograft ex-
periments. In the first, a lymph node metastasis model,
overexpression of miR-4707-5p promoted metastasis of
KYSE30 and KYSE180 cells from the footpad to the popli-
teal lymph nodes (Figures 7A, 7B, and 7D). In the second
assay, a lung metastasis model, overexpression of miR-
4707-5p in KYSE30 and KYSE180 cells led more lung
micrometastases (Figures 7C and 7D). To elucidate the mo-
lecular mechanisms of miR-4707-5p, we conducted a series
of experiments that showed that miR-4707-5p upregulated
b-catenin (MIM: 116806) and downregulated E-cadherin
(MIM: 192090) (Figure 7F and Figure S9A), the master reg-
ulators in the Wnt/b-catenin signaling pathways.51
ADARB1 (MIM: 601218) encodes a site-specific adeno-
sine deaminase that can edit target mRNAs and has been
previously reported as a potential tumor suppressor ins, including deletion, inversion, tandem-duplication, distal-dupli-
ved) identified in WGS study subjects. Each square indicates one
e deletion as indicated; red color indicates the individual carrying
er in ESCC tumor tissues as compared with their adjacent controls,
its transcriptional expression.
with reduced survival of ESCC subjects.
rvival of ESCC subjects.
ecreased cell proliferation (J), colony formation (K), andmigration
analysis of cell-cycle changes in KYSE30 and KYSE410 cells trans-
e. nc, the siRNA negative control with a nonsense and scrambled
test p value < 0.05, **, ##p value < 0.01.
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Figure 5. Analysis of SCNAs in ESCC Genomes and Molecular Characterization of SCNA-Harboring Genes
(A) Recurrent amplifications and deletions identified in WES samples. x axis indicates the chromosome number (autosomes); y axis
indicates the adjusted log ratios (see Material and Methods).
(B) Heatmap plot of the SCNAs identified in 57 WES study subjects. Upper panel presents the hierarchical clustering of the samples
harboring the SCNAs; right panel indicates the proportion of ESCC subjects carrying the observed SCNA.
(C) Plots illustrating the CNV segmentations for chr3, chr8, chr11, and chr14 in WGS samples (see Material and Methods for details of
the relative coverage algorithm and the CNV segmentation method).hepatocellular carcinoma (MIM: 114550).52 Using bio-
informatic tools and luciferase reporter assays (Figure S9B),
we identified ADARB1 as one of important targeted genes
for miR-4707-5p. In vitro, miR-4707-5p downregulated the
protein amount of ADARB1 (Figure 7E) and reversed its
functions (Figures 7F–7I and Figure S9A). In our clinical
cohort (including 120 ESCC-affected individuals with720 The American Journal of Human Genetics 98, 709–727, April 7, 2paraffin sections in the cohort of 321 total subjects), pro-
tein amount of ADARB1 and miR-4707-5p expression
were reversely correlated (Figure 7K). Further, we showed
that ADARB1 was downregulated in ESCC as compared
with adjacent normal tissue, and individuals with tu-
mors expressing lower ADARB1 had poorer survival rates
(Figures 7J and 7L). The TOP-Flash assay, a measure of016
Figure 6. Functional Analysis of Coding and Non-coding Genes Involved in SCNAs
(A) Relative expression levels for protein-coding genes that occurred within regions of recurrent amplifications measured by qPCR from
tumor and adjacent normal tissues.
(B) Relative expression levels for non-coding RNA genes within recurrent amplifications by qPCR in tumor and adjacent normal tissues.
(legend continued on next page)
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Wnt-signaling, was performed to allow us to better
understand the function of miR-4707-5p and ADARB1
(Figure 7G). Transfection of miR-4707-5p into 293T cells
activated b-catenin nuclear signaling, whereas co-transfec-
tion with ADARB1 largely reduced that effect, suggesting
that miR-4707-5p plays a role, at least partially, through
regulating ADARB1. Together, our results suggest thatmiR-
4707-5p-driven depletion of ADARB1 contributes to E-cad-
herin downregulation and b-catenin nuclear signaling,
and we will explore the detailed mechanisms in future
studies.Pathway Enrichment Analyses
We carried out pathway enrichment analyses to explore
how multiple genomic alterations including SCNAs, point
mutations, and differential gene expression might jointly
contribute to ESCC development. These indicated that
somatic mutations were strongly enriched in multiple
functionally linked pathways known to be important in
tumor cell proliferation (e.g., the p53 pathway and the
cell-cycle signaling pathway) and migration (e.g., the
Notch signaling pathway, the Wnt/b-catenin pathway,
and the cadherin signaling pathway) (Figure S10A and Ta-
ble S11). Notably, 93% of samples had somatic mutations
in the cell-cycle signaling pathway, 78% of samples had
genes altered in the p53 pathway, and 91% of samples ex-
hibited exonic somatic mutations in genes involved in
the Wnt/b-catenin pathway. When we clustered samples
by their alterations in the core pathways, they formed a
major group (Figure S10B). Furthermore, these core path-
ways were also the targets of the transcriptionally dysre-
gulated genes impacted by recurrent SVs and/or SCNAs
(e.g., MYBL2 tandem duplications, the recurrent deletions
of CDKN2A, and the recurrent amplifications of FGFs;
Figure S10A). In addition, multiple differentially ex-
pressed genes were found to be enriched in important
cancer pathways such as the cell-cycle pathway and the
p53 signaling pathway (Table S11), suggesting a joint ef-
fect of altered genes at the genomic and transcriptional
levels on ESCC development.Discussion
In this study, we sequenced tumor and normal samples to
characterize somatic events in the genomes of ESCC tu-
mors in order to identify frequently altered genes and(C) Comparisons of gene expression levels of SHANK2, FGF19, LAM
(n ¼ 50).
(D) Comparisons of gene expression levels of miR-1224-3p, miR-4707
cent controls (n ¼ 50).
(E) Kaplan–Meier survival curves of ESCC subjects with different expre
(F–H) Molecular characterization of three noncoding RNA genes, PC
liferation (MTTassay) and cell colony formation for ESCC cell lines ov
proliferation and cell colony formation for ESCC cell lines overexpr
immigration and invasion assays for miR-4707-5p overexpressed in
the bars shown in (F)–(H) represent the mean5 SD; *t test p value <
722 The American Journal of Human Genetics 98, 709–727, April 7, 2core pathways associated with tumorigenesis and prog-
nosis. We identified multiple somatic mutations previ-
ously seen in known cancer pathways and identified
candidate genes for ESCC, including VANGL1 and miR-
4707-5p.
VANGL1, a human homolog of Drosophila tissue po-
larity gene strabismus (stbm), was reported to promote
JNK signaling and inhibit the Wnt/b-catenin signaling
pathway in Drosophila.44 In this study, the results of
in vitro functional experiments showed an anti-pro-
liferative role for VANGL1. Our experiments demonstrated
that VANGL1 inhibited the Wnt/b-catenin signaling
pathway, consistent with its role in Drosophila.44 Previous
studies have reported that VANGL1 promoted tumor
metastasis in colon,53 gastric,54 oral,55 liver,56 and brain57
cancers etc. However, in our study, VANGL1 had no effect
on the migration of ESCC cell lines (Figure S5), which
might indicate that the biological functions of VANGL1
in ESCC are different from the above-mentioned tumor
types.
We found two somatic mutations in VANGL1, one non-
synonymous variant (c.464C>G [p.Ser155Cys]) and one
stop gain (c.1013C>A [p.Ser338*]). We checked the
genotypes for the somatic mutations in VANGL1 and
confirmed that only one allele was affected for each single
somatic mutation. We did not find any SVs or small indels
in this gene. However, we realize that the purity of tumor
samples can distort variant allele frequency due to hetero-
geneous tumor cell clones and mixtures of infiltrating
normal cells. Single-cell sequencing could provide an
alternative method to investigate the VANGL1 mutations
in ESCC tumor cells but was not possible for these studies.
The variant p.Ser155Cys might result in abnormal disul-
fide bond formation between C145 and C149, which
could severely affect folding and thus the stability and
normal activity of VANGL1. The variant p.Ser338* causes
a predicted premature termination of VANGL1 at its cyto-
solic C-terminal domain, resulting in an expected non-
functional truncation. The loss of the C-terminal domain
is expected to abolish interaction with other proteins and
subsequently cause a loss of VANGL1 activity. We believe
our results show that VANGL1 serves as a growth sup-
pressor in the development of ESCC by inhibiting the
Wnt/b-catenin pathway and that reduced expression of
VANGL1 caused by somatic mutations or other mecha-
nisms is consistent with its potential role as a tumor
suppressor.P3, and FADD between ESCC tumor tissues and adjacent controls
-5p, miR-4448, and PCAT1 between ESCC tumor tissues and adja-
ssion levels of SHANK2, FADD,miR-4707-5p, and PCAT1 (n¼ 321).
AT1, miR-1224-3p, and miR-4707-5p. In (F), the results of cell pro-
erexpressing lncRNA PCAT1, respectively. In (G), the results of cell
essing miR-1224-3p, respectively. In H, the analysis results of cell
ESCC cell lines. Experiments were conducted in triplicate. Note:
0.05.
016
Figure 7. miR-4707-5p Promotes Tumor Metastasis and Regulates the Wnt/Beta-Catenin Signaling Pathway by Targeting
ADARB1
(A–D) Analysis of the functions ofmiR-4707-5p in BALB/C-nu/nu nudemice. Experiments were conductedwith lymph nodemodels and
a lung metastasis model. In (A)–(C), the qualitative representations of tumor burden in xenograft nude mice are shown (A and B, pho-
tographs of the lymph node metastasis model and HE staining of lymph nodes with metastases; C, HE staining of lung tissue with
(legend continued on next page)
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At least some of somatically mutated genes we identified
in this study could have potential clinical relevance. The
most promising is NOTCH1, which encodes the key pro-
tein in the Notch signaling pathway. Our study indicated
that ESCC-affected individuals with deleterious NOTCH1
or downregulated gene expression had a better prognosis
(Figures S3B and S3C), consistent with a previous smaller
study.58 This finding indicates that NOTCH1 could be a
promising target for therapeutics. In the NCI60 panel,59
NOTCH1 showed a significant response to 14 existing
anti-cancer drugs including Cytarabine, Dasatinib, Metho-
trexate, and Vinblastine (Table S12). We also identified 19
other somatically mutated genes that were significantly
associated with anti-cancer drug response (Table S12), sug-
gesting that these genes could also be potential targets for
anti-cancer chemotherapy of ESCC.
We believe that the comprehensive characterization
of genes in SCNAs is one of the strengths of this study.
Previous studies have identified oncogenes within the
altered genomic regions, e.g., SOX2 amplification within
3q2647,60 and FBXW7 loss within 4q31.3.61 However,
there has not been a systematic evaluation of SCNAs and
ESCC development and prognosis based on genome
sequencing. Although there are some limitations of the
SCNA analysis with the exome-sequencing data, we con-
ducted real-time PCR quantification for validation of
MYBL2, the miRNA genes, and the other coding genes
(Figure 6). In this study, we found that several miRNA
genes occurring within amplified SCNAs were significantly
associated with ESCC survival, and the mouse xenograft
study showed that one of these, miR-4707-5p, substan-
tially affected metastasis to the lungs and lymph nodes.
From this and other studies, it is increasingly clear that
clinical sequencing of tumor genomes will provide novel
or improved therapeutic strategies for the treatment of
ESCC and other cancers.
In conclusion, we have identified candidate genes that
might play a role in ESCC and confirmed that amplifica-
tion or decreased protein amounts ofMYBL2 and ADARB1
are correlated with shorter survival. We have shown that
at least two of these, VANGL1 and miR-4707-5p, have
experimentally demonstrated roles in cell proliferation,metastases). The arrows indicate the metastatic foci. Scale bars, 200 u
mice with or without metastatic foci was recorded with cell lines tra
(E) ADARB1 abolished the effects ofmiR-4707-5p in ESCC cell lines. In
ADARB1 in KYSE30 and KYSE180.
(F) ADARB1 reversed miR-4707-5p-mediated upregulation of b-cateni
fected with controls; lane 2, cells are transfected with miR-4707-5p m
fected with miR-4707-5p mimics and ADARB1. Mimic controls and p
(G) Luciferase reporter TOP-FLASH assay in HEK293T cells shows in
miR-4707-5p was antagonized by co-transfection of ADARB1. 5 ng o
pcDNA3.1 were used for background adjustment.
(H) The effects of miR-4707-5p overexpression on cell migration wer
(I) Knockdown of ADARB1 mimicked the effects of miR-4707-5p.
(J) IHC staining for ADARB1 in ESCC tumor tissues and adjacent no
(K) The difference in ADARB1 protein levels between miR-4707-5p
indicated.
(L) ADARB1 low-expression individuals have worse prognosis.
The bars shown in (G)–(I) represent the mean5 SD.
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points to potential new pathways and possible targets
for therapy, as well as providing better tools for detection
and predicting prognosis. We have also shown that
genomic events that lead to amplification or loss of genes,
both coding (i.e., MYBL2, FADD, FGF19, SHANK2) and
non-coding (miR-4707-5p, PCAT1), likely play essential
roles in driving tumor development and contributing to
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